Prostate Cancer Hormone Therapy Test – Genomic Prediction
- * Research Study: A study titled "A double-blinded placebo-controlled biomarker stratified randomized trial of apalutamide (APA) and radiotherapy for recurrent prostate cancer (NRG GU006, BALANCE trial)".
Here’s a breakdown of the information provided in the text:
* Research Study: A study titled “A double-blinded placebo-controlled biomarker stratified randomized trial of apalutamide (APA) and radiotherapy for recurrent prostate cancer (NRG GU006, BALANCE trial)”. This is referred to as the “BALANCE trial”.
* Key finding: A new genomic test can predict whether hormone therapy will be beneficial when added to radiation treatment for recurrent prostate cancer.
* Source: The information is provided by the American Society for Radiation Oncology (ASTRO). You can find more information at https://medicalxpress.com/partners/american-society-for-radiation-oncology/ and http://www.astro.org/.
* Publication Date/Retrieval Date: The information was published/retrieved on September 28, 2025.
* Citation: “First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer (2025, September 28) retrieved 28 September 2025” (This is formatted for printing).